🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
This is a prospective, open-label,multicenter Phase II study for evaluating...
Status
Unknown
Location
Multiple Locations
Start Date
2019-03-01
Trial ID
NCT03847818
Treatments Being Tested
This study is a prospective, single-center, open-label, umbrella-shaped pha...
Status
Unknown
Location
Cancer Hospital Affiliated to Fudan University
Start Date
2020-05-01
Trial ID
NCT04355858
This study investigates the efficacy and safety of trastuzumab, pyrotinib c...
Status
Unknown
Location
Multiple Locations
Start Date
2022-10-20
Trial ID
NCT05577442
Treatments Being Tested
In phase Ib, our study is aimed to evaluate the safety and tolerance of SHR...
Status
Recruiting
Location
Fudan Cancer Hospital
Start Date
2025-01-08
Trial ID
NCT06718933
Treatments Being Tested
This is a multi-center, open-lable, prospective, randomized phase III clini...
Status
Active Not Recruiting
Location
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Start Date
2024-01-17
Trial ID
NCT06144944
The purpose of this study is to establish a prospective, single-center plat...
Status
Recruiting
Location
Fudan University Shanghai Cancer Center Shanghai, China, 200032
Start Date
2022-11-01
Trial ID
NCT05582499
Treatments Being Tested
The purpose of this study is to identify the highest tolerable dose of pyro...
Status
Unknown
Location
Multiple Locations
Start Date
2019-08-15
Trial ID
NCT03997539
Treatments Being Tested
Pyrotinib is an important drug for the treatment of breast cancer, but the ...
Status
Unknown
Location
Tianjin Medical University Cancer Institute and Hospital
Start Date
2021-10-08
Trial ID
NCT04988165
Treatments Being Tested
The objective of this study is to evaluate the efficacy of combination of p...
Status
Unknown
Location
Shusen Wang
Start Date
2020-12-04
Trial ID
NCT04334330
Treatments Being Tested
Pyrotinib is an oral tyrosine kinase inhibitor targeting both EGFR and HER-...
Status
Completed
Location
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Start Date
2014-08
Trial ID
NCT02361112
Treatments Being Tested